{"name":"Soligenix","permalink":"soligenix","crunchbase_url":"http://www.crunchbase.com/company/soligenix","homepage_url":"http://www.dorbiopharma.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"","phone_number":"609-538-8200","description":"","created_at":"Wed Jul 07 09:18:17 UTC 2010","updated_at":"Wed Jul 07 09:20:59 UTC 2010","overview":"<p>Soligenix, Inc. is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The Company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early stage development to advanced development and manufacturing. </p>","image":{"available_sizes":[[[150,42],"assets/images/resized/0009/2621/92621v1-max-150x150.jpg"],[[250,70],"assets/images/resized/0009/2621/92621v1-max-250x250.jpg"],[[357,100],"assets/images/resized/0009/2621/92621v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President and CEO","person":{"first_name":"Christopher","last_name":"J. Schaber","permalink":"christopher-j-schaber","image":null}},{"is_past":false,"title":"CFO","person":{"first_name":"Evan","last_name":"Myrianthopoulos","permalink":"evan-myrianthopoulos","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$5.16M","funding_rounds":[{"round_code":"unattributed","source_url":"http://www.dorbiopharma.com/news.aspx?titleId=351","source_description":"Soligenix Announces Private Equity Financing of $5.16 Million with its Partner Sigma-Tau and other Institutional Investors","raised_amount":5160000,"raised_currency_code":"USD","funded_year":2010,"funded_month":6,"funded_day":16,"investments":[{"company":{"name":"Sigma-Tau","permalink":"sigma-tau","image":{"available_sizes":[[[150,48],"assets/images/resized/0007/4322/74322v1-max-150x150.jpg"],[[150,48],"assets/images/resized/0007/4322/74322v1-max-250x250.jpg"],[[150,48],"assets/images/resized/0007/4322/74322v1-max-450x450.jpg"]],"attribution":null}},"financial_org":null,"person":null},{"company":null,"financial_org":{"name":"Downsview Capital","permalink":"downsview-capital","image":null},"person":null},{"company":null,"financial_org":{"name":"Rockmore Capital","permalink":"rockmore-capital","image":null},"person":null},{"company":null,"financial_org":{"name":"OpusPoint Partners","permalink":"opuspoint-partners","image":{"available_sizes":[[[149,69],"assets/images/resized/0006/1685/61685v1-max-150x150.jpg"],[[149,69],"assets/images/resized/0006/1685/61685v1-max-250x250.jpg"],[[149,69],"assets/images/resized/0006/1685/61685v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Iroquois Capital","permalink":"iroquois-capital","image":null},"person":null},{"company":null,"financial_org":{"name":"Dafna Capital Management","permalink":"dafna-capital-management","image":{"available_sizes":[[[150,59],"assets/images/resized/0010/1343/101343v1-max-150x150.jpg"],[[170,67],"assets/images/resized/0010/1343/101343v1-max-250x250.jpg"],[[170,67],"assets/images/resized/0010/1343/101343v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Brio Capital","permalink":"brio-capital","image":{"available_sizes":[[[150,13],"assets/images/resized/0010/0474/100474v1-max-150x150.jpg"],[[241,21],"assets/images/resized/0010/0474/100474v1-max-250x250.jpg"],[[241,21],"assets/images/resized/0010/0474/100474v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Kingsbridge Capital","permalink":"kingsbridge-capital","image":{"available_sizes":[[[150,23],"assets/images/resized/0010/2410/102410v1-max-150x150.jpg"],[[250,38],"assets/images/resized/0010/2410/102410v1-max-250x250.jpg"],[[290,45],"assets/images/resized/0010/2410/102410v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Rosalind Capital Partners","permalink":"rosalind-capital-partners","image":null},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"29 Emmons Drive","address2":"Suite C-10","zip_code":"08540","city":"Princeton","state_code":"NJ","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":{"valuation_amount":null,"valuation_currency_code":"USD","pub_year":null,"pub_month":null,"pub_day":null,"stock_symbol":"OTC:SNGX"},"video_embeds":[],"screenshots":[{"available_sizes":[[[150,76],"assets/images/resized/0009/2620/92620v1-max-150x150.jpg"],[[250,128],"assets/images/resized/0009/2620/92620v1-max-250x250.jpg"],[[450,230],"assets/images/resized/0009/2620/92620v1-max-450x450.jpg"]],"attribution":null}],"external_links":[]}